

Date: 30.05.2025

To
Bombay Stock Exchange Limited
25th Floor, PJ Towers
Dalal Street,
Mumbai-400001
Scrip Code: 524654

To
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051
Symbol: NATCAPSUQ

Subject: Press Release

Dear Sir/ Madam,

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copy of press release made to analysts and investors in connection with Audited Standalone & Consolidated Financial Results for quarter & year ended 31st March,2025.

Request you to please take note of the same.

Thanking You

Yours Faithfully,

For Natural Capsules Limited

Sunil L Mundra
Managing Director
DIN:00214304



NATURAL CAPSULES LIMITED REPORTS Q4 & FY25 RESULTS

Bangalore, May 30th, 2025: Natural Capsules Limited, one of India's leading manufacturer of hard capsules shell has announced its financial results for the fourth quarter and year ended March 31st, 2025.

FINANCIAL HIGHLIGHTS FOR QUARTER ENDED MARCH 31ST, 2025

REVENUES	₹ 44.97 cr	EBITDA	₹ 4.38 cr	EBITDA MARGINS	9.74%
⬆ 2.61%	⬆ 11.81%	⬆ 2.71%	⬆ 6.55%	⬆ 1 BPS	⬇ (48 BPS)
PAT	₹ 0.52 cr	EPS	₹ 0.13	Key	
⬆ 392.62%	⬇ (46.32%)	⬆ 30.00%	⬇ (90.08%)	⬆ Q-o-Q	⬆ Y-o-Y

FINANCIAL HIGHLIGHTS FOR YEAR ENDED MARCH 31ST, 2025

REVENUES	₹ 169.21 cr	EBITDA	₹ 17.52 cr	EBITDA MARGINS	10.35%
	⬆ 8.87%		⬇ (12.01%)		⬇ (246 BPS)
PAT	₹ 0.62 cr	EPS	₹ 0.22	Key	
	⬇ (88.88%)		⬇ (96.47%)		⬆ Y-o-Y

COMMENTING ON THE PERFORMANCE, MR. SUNIL L MUNDRA, EXECUTIVE DIRECTOR, SAID,

"Q4FY25 was a stable period for our capsules business, characterised by steady realisations and robust demand, particularly in our export markets. Notably, towards the end of the quarter, we observed a softening of gelatin prices in international markets—our primary raw material for the capsules business. We anticipate that domestic prices will follow this trend, which should support improved profitability in the coming quarters.

A significant development during the quarter was the imposition of an 88% duty by the US on Chinese HPMC capsules, compared to a 14% duty on Indian HPMC capsules. This substantial price differential has created considerable opportunities for Indian manufacturers in the US market, and we are already experiencing a marked increase in enquiries from these customers. We are reasonably confident that this will translate into a rapid scale-up of our HPMC business in the US over the current financial year.

Looking ahead to FY26, we expect to see an increase in topline driven by our HPMC capsules, which not only command higher realisations but also offer superior profitability. Additionally, the softening of raw material prices should further enhance profitability in our gelatin capsules segment. We have already secured firm orders in the HPMC business, which provides us with strong visibility for an improved performance in the capsules business.

The operating environment in our API segment continues to be challenging, with industry-wide pressure on product realisations due to significant excess capacity in China, leading to heightened competition and declining prices. As our API facility is part of the PLI scheme, we have brought these concerns to the attention of the relevant Indian authorities, who are currently evaluating the introduction of a minimum import price for products manufactured under the PLI. We believe this measure, if implemented, will support the domestic industry and improve operational performance.

As previously guided, our focus this year remains on ramping up capacity utilisation across all products to achieve cash breakeven. During this quarter, we have capitalised the full capacity of our API facility, and expect this to begin impacting consolidated profitability from Q1 FY26, with associated expenses related to interest and depreciation. We anticipate a meaningful pickup in sales from the end of Q2, with sequential improvements throughout the year.

Our priorities for the next financial year are to drive growth and restore higher profitability in the capsules business, while also ramping up capacities in the API segment, aiming for cash breakeven and securing the necessary regulatory approvals that will unlock opportunities for higher-margin business. In conclusion, while the operating environment remains challenging, we are cautiously optimistic and remain steadfast in our commitment to executing our long-term strategies and delivering robust results for all stakeholders."

ABOUT NATURAL CAPSULES LIMITED (NCL)

Natural Capsules Limited (NCL) is a hard capsule shell manufacturer, who pioneered manufacturing of vegetarian capsules in India and is the second largest Indian manufacturer for gelatin capsules. The company was incorporated as a Public Limited Company in 1993 at Bangalore, and it further expanded its operations to Pondicherry in 2003. The company is now foraying into API manufacturing with complex high-end patented technology developed in-house, under its subsidiary company Natural Biogenex Private Limited.

For further details please get in touch with

Raj Kishore Prasad

NATURAL CAPSULES LIMITED

Email: rk.prasad@naturalcapsules.com

Abhishek Mehra

TIL ADVISORS PRIVATE LIMITED

Email: abhishek@theinvestmentlab.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward- looking statements. Natural Capsules Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.